RECURSION PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Share-based Payment Arrangement, Expense of $19.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $19.30M, a 25.18% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $22.00M, a 38.20% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $23.59M, a 22.14% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $25.04M, a 41.15% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2025 was $110.02M, a 38.39% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2024 was $79.50M, a 53.84% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2023 was $51.68M, a 92.32% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2022 was $26.87M, a 94.30% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.30M 10-Q · filed 2026-08-05 | $41.30M 10-Q · filed 2026-08-05 | $64.89M derived: sum of 3 quarters · filed 2026-08-05 | $89.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $22.00M 10-Q · filed 2026-05-06 | $45.58M derived: sum of 2 quarters · filed 2026-05-06 | $70.62M derived: sum of 3 quarters · filed 2026-05-06 | $96.42M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $23.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $48.63M derived: sum of 2 quarters · filed 2026-02-25 | $74.43M derived: sum of 3 quarters · filed 2026-08-05 | $110.02M 10-K · filed 2026-02-25 |
| 2025-09-30 | $25.04M 10-Q · filed 2025-11-05 | $50.84M derived: sum of 2 quarters · filed 2026-08-05 | $86.43M 10-Q · filed 2025-11-05 | $116.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $25.80M 10-Q · filed 2026-08-05 | $61.39M 10-Q · filed 2026-08-05 | $91.68M derived: sum of 3 quarters · filed 2026-08-05 | $109.42M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $35.59M 10-Q · filed 2026-05-06 | $65.88M derived: sum of 2 quarters · filed 2026-05-06 | $83.62M derived: sum of 3 quarters · filed 2026-05-06 | $99.58M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $30.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $48.03M derived: sum of 2 quarters · filed 2026-02-25 | $63.99M derived: sum of 3 quarters · filed 2026-02-25 | $79.50M 10-K · filed 2026-02-25 |
| 2024-09-30 | $17.74M 10-Q · filed 2025-11-05 | $33.70M derived: sum of 2 quarters · filed 2025-11-05 | $49.21M 10-Q · filed 2025-11-05 | $64.89M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $15.96M 10-Q · filed 2025-08-05 | $31.47M 10-Q · filed 2025-08-05 | $47.15M derived: sum of 3 quarters · filed 2026-02-25 | $63.49M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $15.51M 10-Q · filed 2025-05-05 | $31.19M derived: sum of 2 quarters · filed 2026-02-25 | $47.53M derived: sum of 3 quarters · filed 2026-02-25 | $58.92M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $15.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $32.02M derived: sum of 2 quarters · filed 2026-02-25 | $43.41M derived: sum of 3 quarters · filed 2026-02-25 | $51.68M 10-K · filed 2026-02-25 |
| 2023-09-30 | $16.34M 10-Q · filed 2024-11-06 | $27.73M derived: sum of 2 quarters · filed 2024-11-06 | $36.00M 10-Q · filed 2024-11-06 | $43.38M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $11.39M 10-Q · filed 2024-08-08 | $19.66M 10-Q · filed 2024-08-08 | $27.03M derived: sum of 3 quarters · filed 2025-02-28 | $35.69M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $8.27M 10-Q · filed 2024-05-09 | $15.65M derived: sum of 2 quarters · filed 2025-02-28 | $24.30M derived: sum of 3 quarters · filed 2025-02-28 | $29.80M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $7.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $16.03M derived: sum of 2 quarters · filed 2025-02-28 | $21.53M derived: sum of 3 quarters · filed 2025-02-28 | $26.87M 10-K · filed 2025-02-28 |
| 2022-09-30 | $8.65M 10-Q · filed 2023-11-09 | $14.15M derived: sum of 2 quarters · filed 2023-11-09 | $19.50M 10-Q · filed 2023-11-09 | $23.56M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $5.50M 10-Q · filed 2023-08-08 | $10.85M 10-Q · filed 2023-08-08 | $14.90M derived: sum of 3 quarters · filed 2024-02-29 | $18.00M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $5.34M 10-Q · filed 2023-05-08 | $9.40M derived: sum of 2 quarters · filed 2024-02-29 | $12.50M derived: sum of 3 quarters · filed 2024-02-29 | $17.48M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $4.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $7.16M derived: sum of 2 quarters · filed 2024-02-29 | $12.13M derived: sum of 3 quarters · filed 2024-02-29 | $13.83M 10-K · filed 2024-02-29 |
| 2021-09-30 | $3.10M 10-Q · filed 2022-11-08 | $8.07M derived: sum of 2 quarters · filed 2022-11-08 | $9.77M 10-Q · filed 2022-11-08 | $10.75M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $4.98M 10-Q · filed 2022-08-09 | $6.68M 10-Q · filed 2022-08-09 | $7.65M derived: sum of 3 quarters · filed 2023-02-27 | $8.48M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $1.70M 10-Q · filed 2022-05-10 | $2.68M derived: sum of 2 quarters · filed 2023-02-27 | $3.50M derived: sum of 3 quarters · filed 2023-02-27 | $4.27M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $978.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $1.80M derived: sum of 2 quarters · filed 2023-02-27 | $2.57M derived: sum of 3 quarters · filed 2023-02-27 | $3.84M 10-K · filed 2023-02-27 |
| 2020-09-30 | $824.00K 10-Q · filed 2021-11-10 | $1.59M derived: sum of 2 quarters · filed 2021-11-10 | $2.86M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $769.00K 10-Q · filed 2021-08-13 | $2.03M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $1.26M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $1.39M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |